Open AccessThe Effect of Various Types of Anticoagulant Therapy on the Reduction of Mortality in COVID-19
Author(s) -
Alexander Makatsariya,
Е. V. Slukhanchuk,
В. О. Бицадзе,
J. Kh. Khizroeva,
M. V. Tretyakova,
А. С. Шкода,
Ismaı̈l Elalamy,
Gian Carlo Di Renzo,
Giuseppe Rizzo,
N.V. Pyatigorskaya,
А. Г. Солопова,
K. N. Grigoreva,
I. A. Nakaidze,
D. V. Mitryuk
Publication year - 2021
Publication title -
vestnik rossijskoj akademii medicinskih nauk
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.122
H-Index - 15
eISSN - 2414-3545
pISSN - 0869-6047
DOI - 10.15690/vramn1551
Subject(s) - medicine , coagulopathy , intensive care medicine , hemostasis , disseminated intravascular coagulation , anticoagulant therapy , anticoagulant , thrombosis , cytokine storm , sepsis , disease , covid-19 , infectious disease (medical specialty)
Coronavirus disease 2019 (COVID-19) is a viral infection that, in severe course, leads to the development of a cytokine storm, systemic inflammatory response and coagulopathy. Unlike other sepsis-associated disseminated intravascular coagulopathy, COVID-19 induced coagulopathy is realized mainly in thrombosis. Researchers around the world are currently developing adequate diagnostic, monitoring and anticoagulant therapy approaches to safely and effectively manage patients with severe COVID-19. The need to develop laboratory monitoring is due to the fact that 20% of patients have changes in hemostasis indicators, while in patients with a severe form of the disease, they are present in 100% of cases. In case of deaths from COVID-19, there is an increase in the concentration of D-dimer and fibrinogen degradation products. Thus, the severity of hemostasis disorders has an important prognostic value. Anticoagulant therapy is included in the list of all recommendations as an effective means of reducing mortality from COVID-19. The questions of the recommended groups and doses of anticoagulant drugs are still open. The approach to the choice of an anticoagulant should be based not only on risk factors, characteristics of the course of the disease, anamnesis, but also on the wishes of the patient during long-term therapy at the post-hospital stage.